Proteomics-based identification of secreted protein dihydrodiol dehydrogenase 2 as a potential biomarker for predicting cisplatin efficacy in advanced NSCLC patients

Lung Cancer

Volumn 77, Issue 2, 2012, Pages 427-432

  Kuang, Peng ^a   Zhou, Caicun ^a   Li, Xuefei ^a   Ren, Shengxiang ^a   Li, Bing ^a   Wang, Yongsheng ^a   Li, Jiayu ^a   Tang, Liang ^a   Zhang, Jie ^a   Zhao, Yinmin ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biomarker; Chemotherapy; Dihydrodiol dehydrogenase 2 (DDH2); Efficacy; Non small cell lung cancer; Proteomics

Indexed keywords

CISPLATIN; DIHYDRODIOL DEHYDROGENASE; DIHYDRODIOL DEHYDROGENASE 2; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYSTEROID DEHYDROGENASES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEOMICS; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84863776898     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.03.016     Document Type: Article

References (38)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Chang A. Chemotherapy hemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011, 71:3-10.
3. Goldstraw P., Ball D., Jett J.R., Le Chevalier T., Lim E., Nicholson A.G., et al. Non-small-cell lung cancer. Lancet 2011, 378:1727-1740.
4. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
5. Barabas K., Milner R., Lurie D., Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008, 6:1-18.
6. Stewart D.J. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007, 63:12-31.
7. Koberle B., Tomicic M.T., Usanova S., Kaina B. Cisplatin resistance: preclinical findings and clinical implications. Biochim Biophys Acta 2010, 1806:172-182.
8. Wu X., Lu C., Ye Y., Chang J., Yang H., Lin J., et al. Germline genetic variations in drug action pathways predict clinical outcomes in advanced lung cancer treated with platinum-based chemotherapy. Pharmacogenet Genomics 2008, 18:955-965.
9. Lage H. Proteomic approaches for investigation of therapy resistance in cancer. Proteomics Clin Appl 2009, 3:883-911.
10. Yang Y.X., Xiao Z.Q., Chen Z.C., Zhang G.Y., Yi H., Zhang P.F., et al. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics 2006, 6:2009-2021.
11. Chen Y.J., Yuan C.C., Chow K.C., Wang P.H., Lai C.R., Yen M.S., et al. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Gynecol Oncol 2005, 97:110-117.
12. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008, 3:1101-1108.
13. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
14. Vilmar A.C., Sorensen J.B. Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev 2011, 20:45-52.
15. Pathania D., Millard M., Neamati N. Opportunities in discovery and delivery of anticancer drugs targeting mitochondria and cancer cell metabolism. Adv Drug Deliv Rev 2009, 61:1250-1275.
16. King A., Selak M.A., Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 2006, 25:4675-4682.
17. Howell S.B., Niedner H., Christen R., Lin X., Kondo A. Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 2001, 60:1153-1160.
18. Amsterdam A., Hirsh L., Dantes A., Suh B.S., Yoshida Y., Hosokawa K., et al. Phosphodiesterase inhibitors as anti-cancer drugs. Biochem Pharmacol 2004, 68:981-988.
19. Liu X.F., Bera T.K., Liu L.J., Pastan I. A primate-specific POTE-actin fusion protein plays a role in apoptosis. Apoptosis 2009, 14:1237-1244.
20. Bera T.K., Saint Fleur A., Lee Y., Kydd A., Hahn Y., Popescu N.C., et al. POTE paralogs are induced and differentially expressed in many cancers. Cancer Res 2006, 66:52-56.
21. Bera T.K., Zimonjic D.B., Popescu N.C., Sathyanarayana B.K., Kumar V., Lee B., et al. POTE, a highly homologous gene family located on numerous chromosomes and expressed in prostate, ovary, testis, placenta, and prostate cancer. Proc Natl Acad Sci USA 2002, 99:16975-16980.
22. El-Rifai W., Moskaluk C.A., Abdrabbo M.K., Harper J., Yoshida C., Riggins G.J., et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002, 62:6823-6826.
23. Diederichs S., Bulk E., Steffen B., Ji P., Tickenbrock L., Lang K., et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 2004, 64:5564-5569.
24. Myung J.K., Afjehi-Sadat L., Felizardo-Cabatic M., Slavc I., Lubec G. Expressional patterns of chaperones in ten human tumor cell lines. Proteome Sci 2004, 2:8.
25. Agashe V.R., Hartl F.U. Roles of molecular chaperones in cytoplasmic protein folding. Semin Cell Dev Biol 2000, 11:15-25.
26. Harel A., Forbes D.J. Importin beta: conducting a much larger cellular symphony. Mol Cell 2004, 16:319-330.
27. Chook Y.M., Blobel G. Karyopherins and nuclear import. Curr Opin Struct Biol 2001, 11:703-715.
28. Penning T.M., Jin Y., Steckelbroeck S., Lanisnik Rizner T., Lewis M. Structure-function of human 3 [alpha]-hydroxysteroid dehydrogenases: genes and proteins. Mol Cell Endocrinol 2004, 215:63-72.
29. Hsu N.Y, Ho H.C., Chow K.C., Lin T.Y., Shih C.S., Wang L.S., et al. Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res 2001, 61:2727.
30. Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H., et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000, 351:67-77.
31. Deng H.B., Adikari M., Parekh H.K., Simpkins H. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase. Cancer Chemother Pharmacol 2004, 54:301-307.
32. Ueda M., Hung Y.C., Chen J.T., Chiou S.H., Huang H.H., Lin T.Y., et al. Infection of human papillomavirus and overexpression of dihydrodiol dehydrogenase in uterine cervical cancer. Gynecol Oncol 2006, 102:173-181.
33. Tai H.L., Lin T.S., Huang H.H., Lin T.Y., Chou M.C., Chiou S.H., et al. Overexpression of aldo-keto reductase 1C2 as a high-risk factor in bladder cancer. Oncol Rep 2007, 17:305-311.
34. Huang L.J., Chen S.X., Huang Y., Luo W.J., Jiang H.H., Hu Q.H., et al. Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. Lung Cancer 2006, 54:87-94.
35. Ciaccio P.J., Stuart J.E., Tew K.D. Overproduction of a 37.5-kDa cytosolic protein structurally related to prostaglandin F synthase in ethacrynic acid-resistant human colon cells. Mol Pharmacol 1993, 43:845-853.
36. Ax W., Soldan M., Koch L., Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000, 59:293-300.
37. Wang H.W., Lin C.P., Chiu J.H., Chow K.C., Kuo K.T., Lin C.S., et al. Reversal of inflammation-associated dihydrodiol dehydrogenases (AKR1C1 and AKR1C2) overexpression and drug resistance in nonsmall cell lung cancer cells by wogonin and chrysin. Int J Cancer 2007, 120:2019-2027.
38. Pan B.F., Nelson J.A. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas. Cancer Chemo Pharmacol 2007, 59:697-702.